Australian Government-Funded Vaping Education Program Featured in The Lancet: Student Vaping Rates Drop by 65%

Jul.29.2025
Australia’s “OurFutures” vaping education program cut student vaping rates by 65% after 12 months, according to a trial of 5,000 students across 40 schools. Published in The Lancet, it is the first proven effective school-based e-health intervention in Australia. The program will be expanded through 2028, with long-term data expected in 2026.

Key Points:

 

·Project results: The "Our Futures Vaping Prevention Education program" in Australia has significantly reduced the likelihood of teenagers using e-cigarettes, with students involved in the program being 65% less likely to use e-cigarettes 12 months later compared to students who did not participate. 

 

·Research background: The program is funded by the current Australian government and is the first confirmed school-based electronic health intervention program in Australia that can prevent teenagers from using e-cigarettes. 

 

·Research methods: The randomized controlled trial involved 40 schools and over 5000 students, with the results published in The Lancet. 

 

·Project content: The program engages students through cartoon stories, quizzes, and classroom activities, co-designed by young people and teachers to align with national curriculum guidelines. 

 

·Public health significance: The latest data shows a decline in young people using e-cigarettes, with e-cigarette use being increasingly viewed as uncool and socially unacceptable among youth. 

 

·Future plans: The project will be expanded nationwide until 2028, with long-term tracking data expected to be available by 2026.

 


 

【2Firsts News Flash】According to the official website of the Australian government on July 29th, Australia's "Our Futures Vaping Prevention Education program" implemented in schools has achieved tangible results in preventing young people from using e-cigarettes.

 

This randomized controlled trial involved over 5,000 students from 40 schools, and its results were published on July 29th in the top health journal, The Lancet. The study found that students who participated in the program were 65% less likely to use e-cigarettes after 12 months compared to students who did not take part in the course. Additionally, 80% of students reported that the knowledge they gained would help them deal with e-cigarette-related situations in the future.

 

This project is funded by the current Australian government through the Medical Research Future Fund and the National Health and Medical Research Council. It is the first Australian school-based electronic health intervention program proven to prevent adolescents from using e-cigarettes.

 

This program attracts students and delivers information through cartoon stories, quizzes, and classroom activities. It is designed by young people and teachers together to align with the national curriculum.

 

These positive findings are consistent with the latest data on "Generation Vape," which shows a decreasing trend in youth e-cigarette use. E-cigarettes are increasingly being seen as uncool and socially unacceptable among young people.

 

"Our Future" e-cigarette project will be rolled out nationwide until 2028, with long-term tracking data expected to be available by 2026.

 

All high schools are eligible to register and participate in this project, and can do so by signing up immediately.

 

Minister Butler's statement:

 

"'Our Future' e-cigarette prevention education program is helping Australian teenagers make wise choices and resist e-cigarettes. It is smart, scalable, and evidence shows it is effective. This is the evidence-based prevention action we need to protect children's health. Young people are moving away from e-cigarettes. They see its nature - harmful, addictive, and pushed by big tobacco companies. This is proof of the power of education, community, and strong government action."

 

According to publicly available information, The Lancet is one of the oldest and most respected peer-reviewed medical journals in the world, alongside the New England Journal of Medicine, JAMA (Journal of the American Medical Association), and the British Medical Journal, often referred to as the "Big Four" international medical journals.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02
AIR Shares Drop 18.6% in Nasdaq Debut, Testing Hookah’s Move Toward Public Markets
AIR Shares Drop 18.6% in Nasdaq Debut, Testing Hookah’s Move Toward Public Markets
AIR Global’s Nasdaq debut under ticker AIIR ended with a 18.6% first-day decline, giving the global hookah industry a rare public-market reference point. Beyond one company’s share move, the listing raises a broader question: can a culturally rooted, fragmented and venue-based category evolve into a more scalable and investable consumer sector?
Special Report
May.19
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Technology reported financial results on May 7, 2026, for the third quarter of fiscal 2026, covering the three months ended March 31, 2026. Revenue was $18.7 million, compared with $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior quarter. Gross profit was $2.0 million, with gross margin of 10.7%. Net loss was $9.5 million, or $0.17 per share. The company said it held $18.0 million in cash as of March 31, 2026, up $468,000 sequentially.
May.08 by 2FIRSTS.ai
 BAT Bangladesh Cigarette Sales Fall 14%, Q1 Profit Drops 34%
BAT Bangladesh Cigarette Sales Fall 14%, Q1 Profit Drops 34%
British American Tobacco Bangladesh reported a 14% year-on-year decline in cigarette sales volume and a 34% drop in first-quarter profit, highlighting mounting pressure from inflation, taxation, and weakening consumer spending in Bangladesh.
News
May.18
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
Illicit Vape and Nicotine Pouch Seizures Concentrated in UK Hotspots, New Data Shows
Illicit Vape and Nicotine Pouch Seizures Concentrated in UK Hotspots, New Data Shows
Freedom of Information (FOI) data from the UK shows that more than 3,000 seizures of illegal nicotine products were recorded in the 2024/25 financial year, with Hull, Liverpool and Bolton emerging as the most active enforcement hotspots — highlighting that the problem of illicit vapes, nicotine pouches and smokeless tobacco products persists across many parts of the country.
Jun.16